lupus.bmj

Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL)

Objective To examine the impact of different disease activity states (DAS) on outcomes in a longitudinal inception childhood-onset SLE cohort. Materials and methods Three DAS were included—remission: ...
Lupus Science & Medicine

Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort

Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
Lupus Science & Medicine

Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
Lupus Science & Medicine

Prognostic value of baseline clinical features in SLE: a cluster analysis

Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...
lupus.bmj

Methyl-donor supplementation in women with systemic lupus erythematosus with different nutritional status: the protocol for a randomised, double-blind, placebo-controlled trial

Introduction DNA hypomethylation in patients with systemic lupus erythematosus (SLE) has been recently documented in the literature. Low levels of DNA methylation have been observed globally and in ...
lupus.bmj

Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus

Objective This study aimed to characterise the clinical features and treatment regimens of patients with lupus who have lymphadenopathy (LAP), as well as to investigate the presence and potential ...
lupus.bmj

901 Cross-sectional analysis of lupus erythematosus and dermatomyositis stress and cardiovascular health (LEADS-CV) data reveals ideal cardiovascular health is rare in affected ...

Background/Purpose Juvenile lupus (JSLE) and dermatomyositis (JDM) are independent predictors of cardiovascular disease (CVD). The American Heart Association (AHA) defines cardiovascular health (CVH) ...
lupus.bmj

DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus

Objective Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterised by heterogeneous clinical manifestations, autoantibody production and epigenetic dysregulation in T cells. We ...
lupus.bmj

P157 Baricitinib for the treatment of Rhupus Syndrome

Objectives To assess the effectiveness and safety of baricitinib in the treatment of Rhupus. Methods We conducted a retrospective observational review of medical records from the Rheumatology ...
lupus.bmj

Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes

Objective To determine the feasibility and risk of flares by achieving successful glucocorticoid (GC) tapering during the first year of juvenile SLE and the value of early achievement of childhood ...
lupus.bmj

PO:08:209 Safety and efficacy of rituximab to manage pregnancy-related severe flare of systemic lupus erythematosus with new onset lupus nephritis: a case report

We present the case of a 34-year-old with SLE treated initially with hydroxychloroquine (200 mg/daily) and low dose of glucocorticoids(GC). The autoimmune profile revealed positivity for ...
lupus.bmj

15 LLDAS and DORIS remission redefined or refined: the rheumatologist’s perspective

Low disease activity and remission are recognized as important goals in the treatment of patients with lupus and as valuable outcomes in epidemiological research and in clinical trials. The former is ...